Skip to main content

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024 / KEYNOTE-024)

Trial Status: Complete

This is a study to assess the efficacy and safety of pembrolizumab (MK-3475 / SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV, programmed cell death ligand 1 (PD-L1) strong expressing Non-Small Cell Lung Cancer (NSCLC). The primary hypothesis of this study is that participants with PD-L1 strong NSCLC will have a longer Progression Free Survival (PFS), as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) when treated with pembrolizumab than when treated with SOC platinum-based chemotherapies. With Amendment 09 (20 December 2017), once participants have achieved the study objective or the study has ended, participants will be discontinued from this study and enrolled in an extension study to continue protocol-defined assessments and treatment.

Inclusion Criteria

  • Histological or cytological diagnosis of Stage IV NSCLC lacking epidermal growth factor receptor (EGFR)-sensitizing mutation and/or anaplastic lymphoma kinase (ALK) translocation, and received no prior systemic chemotherapy treatment for their metastatic NSCLC
  • At least one radiographically measurable lesion per RECIST 1.1
  • Life expectancy of at least 3 months
  • Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status
  • Adequate organ function
  • No history of prior malignancy, with the exception of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, or in situ cervical cancer, or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy
  • Provided newly obtained formalin fixed tumor tissue from a biopsy of a tumor at the time of or AFTER the diagnosis of metastatic disease has been made AND from a site not previously irradiated
  • PD-L1 strong expressing tumor as determined by immunohistochemistry (IHC) at a central laboratory
  • Female participants must have a negative pregnancy test at screening if of childbearing potential or be of non-childbearing potential
  • Female participants of childbearing potential and male partners with female partners of childbearing potential must agree to use 2 adequate barrier methods of contraception during the study and for 120 days after last dose of study drug and up to 180 days after last dose of chemotherapy

Exclusion Criteria

  • EGFR sensitizing mutation and/or ALK translocation
  • Has received systemic therapy for the treatment of their stage IV NSCLC. Completion of treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant therapy is allowed as long as therapy was completed at least 6 months prior to the diagnosis of metastatic disease.
  • Currently participating or has participated in a study of an investigational agent or using an investigational device within 30 days of first dose of study drug
  • Tumor specimen is not evaluable for PD-L1 expression by the central laboratory
  • Receiving systemic steroid therapy <= 3 days prior to first dose of study drug or receiving any other form of immunosuppressive medication
  • Expected to require any other form of systemic or localized antineoplastic therapy during the study
  • Received prior systemic cytotoxic chemotherapy, biological therapy, major surgery within 3 weeks of first dose of study drug; received thoracic radiation therapy of > 30 gray (Gy) within 6 months of first dose of study drug
  • Received prior therapy with an anti-programmed cell death protein 1 (anti-PD-1), anti-PD-L1, anti-programmed cell death-ligand 2 (anti-PD-L2), anti-CD137 (4-1BB ligand, a member of the Tumor Necrosis Factor Receptor [TNFR] family), or anti-Cytotoxic T-lymphocyte-associated antigen-4 (anti-CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
  • Has untreated central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Active autoimmune disease that has required systemic treatment in past 2 years
  • Allogenic tissue/solid organ transplant
  • Interstitial lung disease or pneumonitis that has required oral or IV steroids
  • Received or will receive a live vaccine within 30 days prior to first dose of study drug
  • Active infection requiring IV systemic therapy
  • Known history of human immunodeficiency virus (HIV)
  • Known active tuberculosis, or hepatitis B or C
  • Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
  • Is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol)
  • Pregnant or breastfeeding, or expecting to conceive or father children during the study and through 120 days after last dose of pembrolizumab or 180 days after last dose of SOC chemotherapy
  • Immediate family member who is investigational site or sponsor staff directly involved with this study


University of Alabama at Birmingham Cancer Center


Los Angeles
Translational Research In Oncology - US Inc
Status: ACTIVE
UCLA / Jonsson Comprehensive Cancer Center
University of California Davis Comprehensive Cancer Center

District of Columbia

MedStar Georgetown University Hospital


Kansas City
University of Kansas Cancer Center


Johns Hopkins University / Sidney Kimmel Cancer Center
Contact: Julie R. Brahmer
Phone: 410-955-8804


Dana-Farber Cancer Institute


Mayo Clinic in Rochester


Saint Louis
Siteman Cancer Center at Washington University


University of Wisconsin Hospital and Clinics

Treatment Phase: Participants randomized to pembrolizumab will be treated for up to 35 cycles

or until documented progressive disease (PD) occurs. Participants randomized to SOC

chemotherapies will be treated with their randomized study drug for up to 4-6 cycles. After

this, participants with non-squamous histologies may choose to be treated with maintenance

pemetrexed for the remainder of the study or until disease progression, unacceptable adverse

event(s) (AEs), intercurrent illness that prevents further administration of treatment,

investigator's decision to withdraw the participant, noncompliance with study treatment or

procedures requirements, the participant receives 35 treatments of study treatment

(pembrolizumab arm only), or administrative reasons. Participants receiving pembrolizumab who

stop drug administration after receiving 35 study treatments for reasons other than disease

progression or intolerability, or participants who attain a complete response and stop study

treatment may be eligible for retreatment with pembrolizumab upon experiencing disease

progression. The decision to retreat with a second course of pembrolizumab will be at the

discretion of the Investigator only if participants meet the criteria for retreatment and the

study is ongoing. Retreatment (second course) is limited to 17 cycles. Participants

randomized to receive SOC chemotherapy may be eligible to receive pembrolizumab if crossover

criteria are met.

Cross-Over Phase: This is only applicable for participants randomized to receive SOC.

Eligible participants will be treated with pembrolizumab for the remainder of the study or

until disease progression, unacceptable AEs, intercurrent illness that prevents further

administration of treatment, investigator's decision to withdraw the participant,

noncompliance with study treatment or procedures requirements, the participant receives 35

treatments of study treatment (pembrolizumab arm only), or administrative reasons.

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Merck and Company Inc

  • Primary ID 3475-024
  • Secondary IDs NCI-2014-01865, 142728, 2014-000323-25, MK-3475-024
  • ID NCT02142738